What's Going On With Huamacyte Shares Tuesday?
What's Going On With Huamacyte Shares Tuesday?
Humacyte, Inc. (NASDAQ:HUMA) stock is trending on Tuesday. In July, the company has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its Acellular Tissue Engineered Vessel.
週二Humacyte, Inc. (NASDAQ:HUMA)股票上漲。7月，該公司已添加約翰·P·班福思博士和基思·安東尼博士到董事會，簽署了與Pluristyx的許可協議，同時獲得美國FDA頒發的再生醫學高級治療(RMAT)藥物治療設計ations爲其無細胞組織工程血管Vessel。
The Details: Humacyte acquired a license for Pluristyx's PluriBank induced Pluripotent Stem Cell (iPSC) line to use as starting materials in the production of insulin-producing cells for their BioVascular Pancreas (BVP) product candidate.
詳情：Humacyte獲得了Pluristyx的PluriBank誘導多能幹細胞(iPSC)系列的許可以用於生產其生物血管胰腺(BVP)候選產品中的產生胰島素的細胞的起始材料。
The BVP aims to treat type 1 diabetes by facilitating the delivery and survival of insulin-producing islets within the body.
BVP旨在通過促進胰島素生產細胞的輸送和存活來治療1型糖尿病。
"The combination of Humacyte's Acellular Tissue Engineered Vessel (ATEV) with insulin-producing cells derived from Pluristyx's best-in-class iPSC lines brings us one step closer to curing insulin dependent diabetes," said Benjamin Fryer, Pluristyx's CEO.
“Humacyte的無細胞組織工程血管和由Pluristyx最佳iPSC系列衍生的產生胰島素的細胞的組合使我們更接近治癒胰島素依賴性糖尿病，”Pluristyx首席執行官本傑明·弗萊爾表示。
"We are excited to assist therapeutic developers in using clinical-grade PluriBank iPSC starting materials."
“我們很高興能幫助治療性研發人員使用臨床級別的PluriBank iPSC起始材料。”
At the start of the month, the company received RMAT designation for the application of Humacyte's ATEV in patients with Advanced Peripheral Artery Disease (PAD). This treatment is particularly beneficial for PAD patients who may not have suitable veins for traditional lower leg bypass procedures.
月初，該公司在Humacyte的無細胞組織工程血管在Advanced Peripheral Artery Disease (PAD)患者中的應用上獲得了RMAt藥物治療設計ations。該治療對於PAD患者尤其有益，因爲他們可能沒有適合傳統下肢搭橋手術的靜脈。
The ATEV is an implantable conduit designed for blood vessel replacement and repair. It has demonstrated low infection rates in clinical trials and is readily available off-the-shelf for immediate surgical use.
ATEV是一種可移植的導管，用於血管置換和修復。在臨床試驗中，感染率低，在醫療機構可立即使用。
Analyst Changes: Multiple analysts have issued price target adjustments throughout July.
分析師變動：多名分析師在7月份發表了對股票的目標價格調整意見。
- BTIG analyst Ryan Zimmerman maintains Humacyte with a Buy and raises the price target from $8 to $11.
- Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte with a Overweight and maintains $7 price target.
- Benchmark analyst Bruce Jackson reiterates Humacyte with a Buy and maintains $15 price target.
- BTIG分析師Ryan Zimmerman 維持Humacyte的買入評級，將目標股價從8美元升至11美元。
- Cantor Fitzgerald的分析師Kristen Kluska重申對Humacyte的看好，維持7美元的目標股價。
- Benchmark的分析師Bruce Jackson重申對Humacyte的買入評級，維持15美元的目標股價。
How To Buy Humacyte Stock
如何購買Humacyte股票
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了手動到經紀所平台購買股票或者部分股票，您還可以通過購買持有股票的ETF，或者在401(k)中分配資金進入一項該類基金或其他工具的策略來獲得股票的份額。例如，Coinbase屬於金融部門。ETF通常持有許多能跟蹤該部門的流動性和大型公司的股票，使投資者能夠獲得該股票板塊內的趨勢。
For example, in Humacyte (NASDAQ:HUMA)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，在Humacyte (NASDAQ:HUMA)的情況下，它屬於醫療保健板塊。ETF通常持有許多可以幫助跟蹤該板塊的流動和大公司的股票，從而使投資者能夠獲得該領域的趨勢。
HUMA Price Action: At the time of publication, Humacyte stock is trading 5.8% higher at $8.89 per data from Benzinga Pro.
HUMA股票走勢：截至發佈時，Humacyte股票的交易價格爲8.89美元，漲幅5.8%。
Image: Michal Jarmoluk from Pixabay
圖片：來自Pixabay的Michal Jarmoluk